<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39308869</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Photonanozyme-Kras-ribosome combination treatment of non-small cell lung cancer after COVID-19.</ArticleTitle><Pagination><StartPage>1420463</StartPage><MedlinePgn>1420463</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1420463</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1420463</ELocationID><Abstract><AbstractText>With the outbreak of the coronavirus disease 2019 (COVID-19), reductions in T-cell function and exhaustion have been observed in patients post-infection of COVID-19. T cells are key mediators of anti-infection and antitumor, and their exhaustion increases the risk of compromised immune function and elevated susceptibility to cancer. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer with high incidence and mortality. Although the survival rate after standard treatment such as surgical treatment and chemotherapy has improved, the therapeutic effect is still limited due to drug resistance, side effects, and recurrence. Recent advances in molecular biology and immunology enable the development of highly targeted therapy and immunotherapy for cancer, which has driven cancer therapies into individualized treatments and gradually entered clinicians' views for treating NSCLC. Currently, with the development of photosensitizer materials, phototherapy has been gradually applied to the treatment of NSCLC. This review provides an overview of recent advancements and limitations in different treatment strategies for NSCLC under the background of COVID-19. We discuss the latest advances in phototherapy as a promising treatment method for NSCLC. After critically examining the successes, challenges, and prospects associated with these treatment modalities, their profound prospects were portrayed.</AbstractText><CopyrightInformation>Copyright © 2024 Si, Bai, Wang, Wang and Qin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Qiaoyan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Engineering, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Mingjian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaolong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tianyu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Biomedical Engineering, Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kras mutants and targeted drugs</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">mammalian target of rapamycin (mTOR) signaling</Keyword><Keyword MajorTopicYN="N">non-small cell lung cancer (NSCLC)</Keyword><Keyword MajorTopicYN="N">photodynamic therapy (PDT)</Keyword><Keyword MajorTopicYN="N">ribosome</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308869</ArticleId><ArticleId IdType="pmc">PMC11412844</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1420463</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. . Cancer incidence and mortality in China, 2015. J Natl Cancer Center. (2021) 1:2–11. doi: 10.1016/j.jncc.2020.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jncc.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC11256613</ArticleId><ArticleId IdType="pubmed">39036787</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. . Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. (2015) 136:E359–E86. doi: 10.1002/ijc.29210</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29210</ArticleId><ArticleId IdType="pubmed">25220842</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA-Cancer J Clin. (2022) 72:7–33. doi: 10.3322/caac.21708</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21708</ArticleId><ArticleId IdType="pubmed">35020204</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday PR, Blakely CM, Bivona TG. Emerging targeted therapies for the treatment of non-small cell lung cancer. Curr Oncol Rep. (2019) 21:12. doi: 10.1007/s11912-019-0770-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-019-0770-x</ArticleId><ArticleId IdType="pubmed">30806814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao SG, Li N, Wang SH, Zhang F, Wei WQ, Li N, et al. . Lung cancer in people’s republic of China. J Thorac Oncol. (2020) 15:1567–76. doi: 10.1016/j.jtho.2020.04.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.04.028</ArticleId><ArticleId IdType="pubmed">32981600</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillon M. Pairing smoking cessation with lung cancer screening may save lives. CA-Cancer J Clin. (2021) 71:283–4. doi: 10.3322/caac.21675</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21675</ArticleId><ArticleId IdType="pubmed">34061366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates JHT, Hamlington KL, Garrison G, Kinsey CM. Prediction of lung cancer risk based on age and smoking history. Comput Meth Programs BioMed. (2022) 216:6. doi: 10.1016/j.cmpb.2022.106660</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2022.106660</ArticleId><ArticleId IdType="pmc">PMC8920760</ArticleId><ArticleId IdType="pubmed">35114461</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CL, Wang YM, Li XW, Ren LL, Zhao JP, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/s0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkrief A, Hennessy C, Kuderer NM, Rubinstein SM, Wulff-Burchfield E, Rosovsky RP, et al. . Geriatric risk factors for serious covid-19 outcomes among older adults with cancer: A cohort study from the covid-19 and cancer consortium. Lancet Healthy Longev. (2022) 3:e143–e52. doi: 10.1016/s2666-7568(22)00009-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-7568(22)00009-5</ArticleId><ArticleId IdType="pmc">PMC8843069</ArticleId><ArticleId IdType="pubmed">35187516</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrò L, Rossi G, Covre A, Morra A, Maio M. Covid and lung cancer. Curr Oncol Rep. (2021) 23(11). doi: 10.1007/s11912-021-01125-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11912-021-01125-8</ArticleId><ArticleId IdType="pmc">PMC8532085</ArticleId><ArticleId IdType="pubmed">34677721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogado J, Pangua C, Serrano-Montero G, Obispo B, Marino AM, Pérez-Pérez M, et al. . Covid-19 and lung cancer: A greater fatality rate? Lung Cancer. (2020) 146:19–22. doi: 10.1016/j.lungcan.2020.05.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2020.05.034</ArticleId><ArticleId IdType="pmc">PMC7260554</ArticleId><ArticleId IdType="pubmed">32505076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfo C, Meshulami N, Russo A, Krammer F, García-Sastre A, Mack PC, et al. . Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation. J Thorac Oncol. (2022) 17:214–27. doi: 10.1016/j.jtho.2021.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8579698</ArticleId><ArticleId IdType="pubmed">34774792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Zhang C, Zhao X. The impact of covid-19 pandemic on lung cancer community. World J Oncol. (2021) 12:1–6. doi: 10.14740/wjon1367</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/wjon1367</ArticleId><ArticleId IdType="pmc">PMC7935618</ArticleId><ArticleId IdType="pubmed">33738000</ArticleId></ArticleIdList></Reference><Reference><Citation>Aramini B, Masciale V, Samarelli AV, Tonelli R, Cerri S, Clini E, et al. . Biological effects of covid-19 on lung cancer: can we drive our decisions. Front Oncol. (2022) 12:1029830. doi: 10.3389/fonc.2022.1029830</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2022.1029830</ArticleId><ArticleId IdType="pmc">PMC9589049</ArticleId><ArticleId IdType="pubmed">36300087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaqub F. Thoracoscopic lobectomy versus thoracotomy for nsclc. Lancet Oncol. (2014) 15:E535–E. doi: 10.1016/s1470-2045(14)71024-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(14)71024-1</ArticleId><ArticleId IdType="pubmed">25602111</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno AC, Fellman B, Hobbs BP, Liao ZX, Gomez DR, Chen A, et al. . Biologically effective dose in stereotactic body radiotherapy and survival for patients with early-stage nsclc. J Thorac Oncol. (2020) 15:101–9. doi: 10.1016/j.jtho.2019.08.2505</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2019.08.2505</ArticleId><ArticleId IdType="pubmed">31479748</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst RS, Sznol M. Diminished but not dead: chemotherapy for the treatment of nsclc. Lancet Oncol. (2016) 17:1464–5. doi: 10.1016/s1470-2045(16)30524-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(16)30524-1</ArticleId><ArticleId IdType="pubmed">27819227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson L. Targeted therapies: defining the best-in-class in nsclc. Nat Rev Clin Oncol. (2017) 14:457. doi: 10.1038/nrclinonc.2017.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.99</ArticleId><ArticleId IdType="pubmed">28653679</ArticleId></ArticleIdList></Reference><Reference><Citation>Gridelli C, Casaluce F. Lung cancer frontline immunotherapy for nsclc: alone or not alone? Nat Rev Clin Oncol. (2018) 15:593–4. doi: 10.1038/s41571-018-0070-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-018-0070-7</ArticleId><ArticleId IdType="pubmed">29993034</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Harada M, Ichinose S, Usuda J, Tsuchida T, Okunaka T. Photodynamic therapy (Pdt) of lung cancer: experience of the Tokyo medical university. Photodiagnosis Photodyn Ther. (2004) 1:49–55. doi: 10.1016/s1572-1000(04)00008-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1572-1000(04)00008-0</ArticleId><ArticleId IdType="pubmed">25048064</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol. (2002) 20:2217–9. doi: 10.1200/jco.2002.20.9.2217</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2002.20.9.2217</ArticleId><ArticleId IdType="pubmed">11980990</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao DW, Habib AA. Ligand-independent egfr signaling. Cancer Res. (2015) 75:3436–41. doi: 10.1158/0008-5472.Can-15-0989</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-15-0989</ArticleId><ArticleId IdType="pmc">PMC4558210</ArticleId><ArticleId IdType="pubmed">26282175</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang LH, Fu LW. Mechanisms of resistance to egfr tyrosine kinase inhibitors. Acta Pharm Sin B. (2015) 5:390–401. doi: 10.1016/j.apsb.2015.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4629442</ArticleId><ArticleId IdType="pubmed">26579470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. (2007) 7:169–81. doi: 10.1038/nrc2088</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2088</ArticleId><ArticleId IdType="pubmed">17318210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarden Y, Shilo BZ. Snapshot: egfr signaling pathway. Cell. (2007) 131:2. doi: 10.1016/j.cell.2007.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.013</ArticleId><ArticleId IdType="pubmed">18045542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. (2001) 7(10):2958–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">11595683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. (2009) 361:958–U38. doi: 10.1056/NEJMoa0904554</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0904554</ArticleId><ArticleId IdType="pubmed">19692684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu WH, Yang JCH, Mok TS, Loong HH. Overview of current systemic management of egfr-mutant nsclc. Ann Oncol. (2018) 29:I3–9. doi: 10.1093/annonc/mdx702</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx702</ArticleId><ArticleId IdType="pubmed">29462253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahsan A. Mechanisms of resistance to egfr tyrosine kinase inhibitors and therapeutic approaches: an update. In: Ahmad A, Gadgeel S, editors. Lung Cancer and Personalized Medicine: Current Knowledge and Therapies. Advances in Experimental Medicine and Biology, vol. 893. Springer International Publishing Ag, Cham: (2016). p. 137–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26667342</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazdar AF. Activating and resistance mutations of egfr in non-small-cell lung cancer: role in clinical response to egfr tyrosine kinase inhibitors. Oncogene. (2009) 28:S24–31. doi: 10.1038/onc.2009.198</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.198</ArticleId><ArticleId IdType="pmc">PMC2849651</ArticleId><ArticleId IdType="pubmed">19680293</ArticleId></ArticleIdList></Reference><Reference><Citation>Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation egfr tki in egfr-mutant nsclc patients. Ann Oncol. (2018) 29:I20–I7. doi: 10.1093/annonc/mdx704</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdx704</ArticleId><ArticleId IdType="pubmed">29462255</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. (2010) 11:1343–57. doi: 10.1517/14656566.2010.481283</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2010.481283</ArticleId><ArticleId IdType="pubmed">20426712</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JCH, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, et al. . Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced nsclc with sensitizing egfr mutation. J Thorac Oncol. (2019) 14:553–9. doi: 10.1016/j.jtho.2018.11.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2018.11.028</ArticleId><ArticleId IdType="pubmed">30529597</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu X, Zeng LZ, Shi J, Ming ZJ, Li W, Liu BX, et al. . Essential role for stat3/foxm1/atg7 signaling-dependent autophagy in resistance to icotinib. J Exp Clin Cancer Res. (2022) 41:14. doi: 10.1186/s13046-022-02390-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-022-02390-6</ArticleId><ArticleId IdType="pmc">PMC9188165</ArticleId><ArticleId IdType="pubmed">35690866</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, et al. . Possible differential egfr-tki efficacy among exon 19 deletional locations in egfr-mutant non-small cell lung cancer. Lung Cancer. (2014) 86:213–8. doi: 10.1016/j.lungcan.2014.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2014.09.014</ArticleId><ArticleId IdType="pubmed">25304185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon CS, Lin HM, Crossland V, Churchill EN, Curran E, Forsythe A, et al. . Non-small cell lung cancer with egfr exon 20 insertion mutation: A systematic literature review and meta-analysis of patient outcomes. Curr Med Res Opin. (2022) 38:1341–50. doi: 10.1080/03007995.2022.2083326</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2083326</ArticleId><ArticleId IdType="pubmed">35621011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for nsclc. OncoTargets Ther. (2013) 6:135–43. doi: 10.2147/ott.S23165</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ott.S23165</ArticleId><ArticleId IdType="pmc">PMC3594037</ArticleId><ArticleId IdType="pubmed">23493883</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidaway P. Dacomitinib delays disease progression. Nat Rev Clin Oncol. (2017) 14:712–. doi: 10.1038/nrclinonc.2017.162</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2017.162</ArticleId><ArticleId IdType="pubmed">28994420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. . Egfr mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. (2005) 352:786–92. doi: 10.1056/NEJMoa044238</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa044238</ArticleId><ArticleId IdType="pubmed">15728811</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. . Analysis of tumor specimens at the time of acquired resistance to egfr-tki therapy in 155 patients with egfr-mutant lung cancers. Clin Cancer Res. (2013) 19:2240–7. doi: 10.1158/1078-0432.Ccr-12-2246</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-12-2246</ArticleId><ArticleId IdType="pmc">PMC3630270</ArticleId><ArticleId IdType="pubmed">23470965</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. . The T790m mutation in egfr kinase causes drug resistance by increasing the affinity for atp. Proc Natl Acad Sci USA. (2008) 105:2070–5. doi: 10.1073/pnas.0709662105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0709662105</ArticleId><ArticleId IdType="pmc">PMC2538882</ArticleId><ArticleId IdType="pubmed">18227510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerbone L, Benitez JC, Planchard D, Genova C. An overview of osimertinib as a treatment of non-small cell lung cancer (Nsclc): an update. Expert Opin Pharmacother. (2021) 22:12. doi: 10.1080/14656566.2021.1888928</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2021.1888928</ArticleId><ArticleId IdType="pubmed">33593225</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JCH, Camidge DR, Yang CT, Zhou JY, Guo RH, Chiu CH, et al. . Safety, efficacy, and pharmacokinetics of almonertinib (Hs-10296) in pretreated patients with egfr-mutated advanced nsclc: A multicenter, open-label, phase 1 trial. J Thorac Oncol. (2020) 15:1907–18. doi: 10.1016/j.jtho.2020.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.09.001</ArticleId><ArticleId IdType="pubmed">32916310</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks ED. Furmonertinib: first approval. Drugs. (2021) 81:1775–80. doi: 10.1007/s40265-021-01588-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01588-w</ArticleId><ArticleId IdType="pubmed">34528187</ArticleId></ArticleIdList></Reference><Reference><Citation>Jukna A, Montanari G, Mengoli MC, Cavazza A, Covi M, Barbieri F, et al. . Squamous cell carcinoma “Transformation” Concurrent with secondary T790m mutation in resistant egfr-mutated adenocarcinomas. J Thorac Oncol. (2016) 11:E49–51. doi: 10.1016/j.jtho.2015.12.096</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2015.12.096</ArticleId><ArticleId IdType="pubmed">26746366</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan GJ, Lou LL, Song ZD, Zhang XL, Xiong XF. Targeting mutated gtpase kras in tumor therapies. Eur J Med Chem. (2021) 226:18. doi: 10.1016/j.ejmech.2021.113816</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113816</ArticleId><ArticleId IdType="pubmed">34520956</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, et al. . Drugging kras: current perspectives and state-of-art review. J Hematol Oncol. (2022) 15:22. doi: 10.1186/s13045-022-01375-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-022-01375-4</ArticleId><ArticleId IdType="pmc">PMC9597994</ArticleId><ArticleId IdType="pubmed">36284306</ArticleId></ArticleIdList></Reference><Reference><Citation>Prior IA, Hood FE, Hartley JL. The frequency of ras mutations in cancer. Cancer Res. (2020) 80:2969–74. doi: 10.1158/0008-5472.Can-19-3682</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-19-3682</ArticleId><ArticleId IdType="pmc">PMC7367715</ArticleId><ArticleId IdType="pubmed">32209560</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogan S, Shen RL, Ang DC, Johnson ML, D’Angelo SP, Paik PK, et al. . Molecular epidemiology of egfr and kras mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related kras-mutant cancers. Clin Cancer Res. (2012) 18:6169–77. doi: 10.1158/1078-0432.Ccr-11-3265</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-11-3265</ArticleId><ArticleId IdType="pmc">PMC3500422</ArticleId><ArticleId IdType="pubmed">23014527</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, et al. . Prognostic impact of kras G12c mutation in patients with nsclc: results from the European thoracic oncology platform lungscape project. J Thorac Oncol. (2021) 16:990–1002. doi: 10.1016/j.jtho.2021.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2021.02.016</ArticleId><ArticleId IdType="pubmed">33647504</ArticleId></ArticleIdList></Reference><Reference><Citation>Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. . Comprehensive molecular profiling of lung adenocarcinoma. Nature. (2014) 511:543–50. doi: 10.1038/nature13385</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13385</ArticleId><ArticleId IdType="pmc">PMC4231481</ArticleId><ArticleId IdType="pubmed">25079552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. Cancer gene mutation frequencies for the U.S. Population. Nat Commun. (2021) 12(1). doi: 10.1038/s41467-021-26213-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26213-y</ArticleId><ArticleId IdType="pmc">PMC8514428</ArticleId><ArticleId IdType="pubmed">34645806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathiot L, Herbreteau G, Robin S, Fenat C, Bennouna J, Blanquart C, et al. . Hras Q61l mutation as a possible target for non-small cell lung cancer: case series and review of literature. Curr Oncol. (2022) 29:3748–58. doi: 10.3390/curroncol29050300</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol29050300</ArticleId><ArticleId IdType="pmc">PMC9139372</ArticleId><ArticleId IdType="pubmed">35621690</ArticleId></ArticleIdList></Reference><Reference><Citation>End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, et al. . Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro . Cancer Res. (2001) 61(1):131–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11196150</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskoski R. Blockade of mutant ras oncogenic signaling with a special emphasis on kras. Pharmacol Res. (2021) 172. doi: 10.1016/j.phrs.2021.105806</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105806</ArticleId><ArticleId IdType="pubmed">34450320</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore AR, Rosenberg SC, McCormick F, Malek S. Ras-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. (2020) 19:533–52. doi: 10.1038/s41573-020-0068-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0068-6</ArticleId><ArticleId IdType="pmc">PMC7809886</ArticleId><ArticleId IdType="pubmed">32528145</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood K, Hensing T, Malik R, Salgia R. Prognostic and predictive value in kras in non-small-cell lung cancer a review. JAMA Oncol. (2016) 2:805–12. doi: 10.1001/jamaoncol.2016.0405</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.0405</ArticleId><ArticleId IdType="pubmed">27100819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherfils J, Zeghouf M. Regulation of small gtpases by gefs, gaps, and gdis. Physiol Rev. (2013) 93:269–309. doi: 10.1152/physrev.00003.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00003.2012</ArticleId><ArticleId IdType="pubmed">23303910</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily gefs and gaps: validated and tractable targets for cancer therapy? Nat Rev Cancer. (2010) 10:842–57. doi: 10.1038/nrc2960</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2960</ArticleId><ArticleId IdType="pmc">PMC3124093</ArticleId><ArticleId IdType="pubmed">21102635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XF, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS, et al. . Normal and oncogenic P21ras proteins bind to the amino-terminal regulatory domain of C-raf-1. Nature. (1993) 364:308–13. doi: 10.1038/364308a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364308a0</ArticleId><ArticleId IdType="pubmed">8332187</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. . Phosphatidylinositol-3-oh kinase as a direct target of ras. Nature. (1994) 370:527–32. doi: 10.1038/370527a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/370527a0</ArticleId><ArticleId IdType="pubmed">8052307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjolander A, Yamamoto K, Huber BE, Lapetina EG. Association of P21ras with phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA. (1991) 88:7908–12. doi: 10.1073/pnas.88.18.7908</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.18.7908</ArticleId><ArticleId IdType="pmc">PMC52414</ArticleId><ArticleId IdType="pubmed">1716764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kikuchi A, Demo SD, Ye ZH, Chen YW, Williams LT. Ralgds family members interact with the effector loop of ras P21. Mol Cell Biol. (1994) 14:7483–91. doi: 10.1128/mcb.14.11.7483</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mcb.14.11.7483</ArticleId><ArticleId IdType="pmc">PMC359284</ArticleId><ArticleId IdType="pubmed">7935463</ArticleId></ArticleIdList></Reference><Reference><Citation>Menyhárd DK, Pálfy G, Orgován Z, Vida I, Keseru GM, Perczel A. Structural impact of gtp binding on downstream kras signaling. Chem Sci. (2020) 11:9272–89. doi: 10.1039/d0sc03441j</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0sc03441j</ArticleId><ArticleId IdType="pmc">PMC8161693</ArticleId><ArticleId IdType="pubmed">34094198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Wang Y, Li S, Zhou A, Qin Y. Organelle biogenesis: ribosomes as organizer and performer. Sci Bull. (2022) 67:1614–7. doi: 10.1016/j.scib.2022.07.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scib.2022.07.023</ArticleId><ArticleId IdType="pubmed">36546035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Brajanovski N, Chan KT, Xuan JC, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. (2021) 6:22. doi: 10.1038/s41392-021-00728-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00728-8</ArticleId><ArticleId IdType="pmc">PMC8405630</ArticleId><ArticleId IdType="pubmed">34462428</ArticleId></ArticleIdList></Reference><Reference><Citation>American Association for Cancer Research . Fda approves first kras inhibitor: sotorasib. Cancer Discov. (2021) 11:OF4. doi: 10.1158/2159-8290.Cd-nb2021-0362</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-nb2021-0362</ArticleId><ArticleId IdType="pubmed">34158284</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. . Sotorasib for lung cancers with kras P. G12c Mutation. N Engl J Med. (2021) 384:2371–81. doi: 10.1056/NEJMoa2103695</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2103695</ArticleId><ArticleId IdType="pmc">PMC9116274</ArticleId><ArticleId IdType="pubmed">34096690</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon S. Adagrasib: first approval. Drugs. (2023) 11. doi: 10.1007/s40265-023-01839-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01839-y</ArticleId><ArticleId IdType="pubmed">36763320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaenne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. . Adagrasib in non-small-cell lung cancer harboring a kras G12c mutation. N Engl J Med. (2022) 387:120–31. doi: 10.1056/NEJMoa2204619</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204619</ArticleId><ArticleId IdType="pubmed">35658005</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen JG, Hallin J. The krasG12d inhibitor mrtx1133 elucidates kras-mediated oncogenesis. Nat Med. (2022) 28:2017–8. doi: 10.1038/s41591-022-02008-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02008-6</ArticleId><ArticleId IdType="pubmed">36207523</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaccaro SL, Prigent P, Le Bail JC, Dos-Santos O, Dassencourt L, Eskandar M, et al. . Tead inhibitors sensitize krasG12c inhibitors via dual cell cycle arrest in krasG12c-mutant nsclc. Pharmaceuticals. (2023) 16:20. doi: 10.3390/ph16040553</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16040553</ArticleId><ArticleId IdType="pmc">PMC10142471</ArticleId><ArticleId IdType="pubmed">37111311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Herdeis L, Rudolph D, Zhao YL, Böttcher J, Vides A, et al. . Pan-kras inhibitor disables oncogenic signalling and tumour growth. Nature. (2023) 619:160. doi: 10.1038/s41586-023-06123-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06123-3</ArticleId><ArticleId IdType="pmc">PMC10322706</ArticleId><ArticleId IdType="pubmed">37258666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Shavit R, Maoz M, Kancharla A, Nag JK, Agranovich D, Grisaru-Granovsky S, et al. . G protein-coupled receptors in cancer. Int J Mol Sci. (2016) 17:16. doi: 10.3390/ijms17081320</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17081320</ArticleId><ArticleId IdType="pmc">PMC5000717</ArticleId><ArticleId IdType="pubmed">27529230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilardaga JP, Bünemann M, Feinstein TN, Lambert N, Nikolaev VO, Engelhardt S, et al. . Minireview: gpcr and G proteins: drug efficacy and activation in live cells. Mol Endocrinol. (2009) 23:590–9. doi: 10.1210/me.2008-0204</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2008-0204</ArticleId><ArticleId IdType="pmc">PMC5419261</ArticleId><ArticleId IdType="pubmed">19196832</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagareddy PR, Chow FL, Hao L, Wang X, Nishimura T, MacLeod KM, et al. . Maintenance of adrenergic vascular tone by mmp transactivation of the egfr requires pi3k and mitochondrial atp synthesis. Cardiovasc Res. (2009) 84:368–77. doi: 10.1093/cvr/cvp230</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvp230</ArticleId><ArticleId IdType="pubmed">19578070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WJ, Qiao YH, Li ZJ. New insights into modes of gpcr activation. Trends Pharmacol Sci. (2018) 39:367–86. doi: 10.1016/j.tips.2018.01.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2018.01.001</ArticleId><ArticleId IdType="pubmed">29395118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XW, Li L, Hu WQ, Hu MN, Tao Y, Hu H, et al. . Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of egfr. Cell Death Dis. (2022) 13:15. doi: 10.1038/s41419-021-04485-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04485-y</ArticleId><ArticleId IdType="pmc">PMC8748918</ArticleId><ArticleId IdType="pubmed">35013118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QS, Zhang TS, Chang XY, Wang KK, Lee MH, Ma WY, et al. . Targeting opsin4/melanopsin with a novel small molecule suppresses pkc/raf/mek/erk signaling and inhibits lung adenocarcinoma progression. Mol Cancer Res. (2020) 18:1028–38. doi: 10.1158/1541-7786.Mcr-19-1120</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.Mcr-19-1120</ArticleId><ArticleId IdType="pubmed">32269074</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, et al. . Antitumor mechanisms of targeting the pdk1 pathway in head and neck cancer. Mol Cancer Ther. (2012) 11:1236–46. doi: 10.1158/1535-7163.Mct-11-0936</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.Mct-11-0936</ArticleId><ArticleId IdType="pmc">PMC3413198</ArticleId><ArticleId IdType="pubmed">22491800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YH, Lim J, Wu KC, Xu WJ, Suen JY, Fairlie DP. Par2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate egfr. Br J Pharmacol. (2021) 178:913–32. doi: 10.1111/bph.15332</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15332</ArticleId><ArticleId IdType="pubmed">33226635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodali R, Hajjou M, Berman AB, Bansal MB, Zhang SH, Pan JJ, et al. . Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells. Cardiovasc Res. (2006) 69:706–15. doi: 10.1016/j.cardiores.2005.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2005.09.012</ArticleId><ArticleId IdType="pubmed">16343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallifatidis G, Munoz D, Singh RK, Salazar N, Hoy JJ, Lokeshwar BL. B-arrestin-2 counters cxcr7-mediated egfr transactivation and proliferation. Mol Cancer Res. (2016) 14:493–503. doi: 10.1158/1541-7786.Mcr-15-0498</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.Mcr-15-0498</ArticleId><ArticleId IdType="pmc">PMC4867265</ArticleId><ArticleId IdType="pubmed">26921391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus S, Benard O, Naor Z, Seger R. Retraction: C-src is activated by the epidermal growth factor receptor in a pathway that mediates jnk and erk activation by gonadotropin-releasing hormone in cos7 cells (Retraction of vol 278, pg 32618, 2003). J Biol Chem. (2017) 292:8851–. doi: 10.1074/jbc.A117.303886</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.A117.303886</ArticleId><ArticleId IdType="pmc">PMC5448115</ArticleId><ArticleId IdType="pubmed">28550137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wetzker R, Böhmer FD. Transactivation joins multiple tracks to the erk/mapk cascade. Nat Rev Mol Cell Biol. (2003) 4:651–7. doi: 10.1038/nrm1173</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm1173</ArticleId><ArticleId IdType="pubmed">12923527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zia F, Fagarasan M, Bitar K, Coy DH, Pisegna JR, Wank SA, et al. . Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. Cancer Res. (1995) 55(21):4886–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719695</ArticleId><ArticleId IdType="pubmed">7585525</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (Grac), 3rd edition. Br J Pharmacol. (2008) 153:S1–S209. doi: 10.1038/sj.bjp.0707746</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0707746</ArticleId><ArticleId IdType="pmc">PMC2275471</ArticleId><ArticleId IdType="pubmed">18347570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience. (2011) 193:440–51. doi: 10.1016/j.neuroscience.2011.06.085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.06.085</ArticleId><ArticleId IdType="pubmed">21763756</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell FA, Schuelert N, Veldhoen VE, Hollenberg MD, McDougall JJ. Activation of par2 receptors sensitizes primary afferents and causes leukocyte rolling and adherence in the rat knee joint. Br J Pharmacol. (2012) 167:1665–78. doi: 10.1111/j.1476-5381.2012.02120.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2012.02120.x</ArticleId><ArticleId IdType="pmc">PMC3525869</ArticleId><ArticleId IdType="pubmed">22849826</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar NR, Buzza MS, Antalis TM. Membrane-anchored serine proteases and protease-activated receptor-2-mediated signaling: co-conspirators in cancer progression. Cancer Res. (2019) 79:301–10. doi: 10.1158/0008-5472.Can-18-1745</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-18-1745</ArticleId><ArticleId IdType="pmc">PMC6335149</ArticleId><ArticleId IdType="pubmed">30610085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Li PB, Yao YF, Xiu AY, Peng Z, Bai YH, et al. . Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol. (2018) 24:1120–33. doi: 10.3748/wjg.v24.i10.1120</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v24.i10.1120</ArticleId><ArticleId IdType="pmc">PMC5850131</ArticleId><ArticleId IdType="pubmed">29563756</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer - trypsin-induced mapk phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. (2004) 279:20927–34. doi: 10.1074/jbc.M401430200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401430200</ArticleId><ArticleId IdType="pubmed">15010475</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M. Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res. (2004) 2:514–22. doi: 10.1158/1541-7786.514.2.9</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.514.2.9</ArticleId><ArticleId IdType="pubmed">15383630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YH, Zhuo X, Fu XJ, Wu Y, Mao CQ. Targeting par2 overcomes gefitinib resistance in non-small-cell lung cancer cells through inhibition of egfr transactivation. Front Pharmacol. (2021) 12:625289. doi: 10.3389/fphar.2021.625289</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.625289</ArticleId><ArticleId IdType="pmc">PMC8100583</ArticleId><ArticleId IdType="pubmed">33967759</ArticleId></ArticleIdList></Reference><Reference><Citation>Köse M. Gpcrs and egfr - cross-talk of membrane receptors in cancer. Bioorg Med Chem Lett. (2017) 27:3611–20. doi: 10.1016/j.bmcl.2017.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2017.07.002</ArticleId><ArticleId IdType="pubmed">28705643</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Zhuo X, Wu Y, Fu X, Mao C. Par2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating erk-mediated emt and pd-L1 expression. Biochim Biophys Acta (BBA) - Mol Cell Res. (2022) 1869(1). doi: 10.1016/j.bbamcr.2021.119144</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.119144</ArticleId><ArticleId IdType="pubmed">34599981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. (2018) 834:188–96. doi: 10.1016/j.ejphar.2018.07.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.07.034</ArticleId><ArticleId IdType="pubmed">30031797</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Kurzrock R. Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms. Cancer Treat Rev. (2014) 40:883–91. doi: 10.1016/j.ctrv.2014.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2014.05.003</ArticleId><ArticleId IdType="pubmed">24867380</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmani L, Askin F, Gabrielson E, Li QK. Current who guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (Nsclc): moving from targeted therapy to immunotherapy. Semin Cancer Biol. (2018) 52:103–9. doi: 10.1016/j.semcancer.2017.11.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2017.11.019</ArticleId><ArticleId IdType="pmc">PMC5970946</ArticleId><ArticleId IdType="pubmed">29183778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. . Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. (2023) 22:37. doi: 10.1186/s12943-023-01740-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-023-01740-y</ArticleId><ArticleId IdType="pmc">PMC9942077</ArticleId><ArticleId IdType="pubmed">36810079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, et al. . Immunotherapy in nsclc: A promising and revolutionary weapon. In: Naing A, Hajjar J, editors. Immunotherapy. Advances in Experimental Medicine and Biology, vol. 995 . Springer International Publishing Ag, Cham: (2017). p. 97–125.</Citation><ArticleIdList><ArticleId IdType="pubmed">28321814</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Tu JY, Wang X, Chu Q. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. (2019) 11:429–41. doi: 10.2217/imt-2018-0110</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2018-0110</ArticleId><ArticleId IdType="pubmed">30698054</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoury SC, Straughan DM, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. (2015) 15:452–62. doi: 10.2174/156800961506150805145120</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156800961506150805145120</ArticleId><ArticleId IdType="pubmed">26282545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, et al. . A consensus on immunotherapy from the 2017 Chinese lung cancer summit expert panel. Transl Lung Cancer Res. (2018) 7:428–36. doi: 10.21037/tlcr.2018.04.15</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr.2018.04.15</ArticleId><ArticleId IdType="pmc">PMC6037958</ArticleId><ArticleId IdType="pubmed">30050780</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui PF, Li RX, Huang ZW, Wu ZZ, Tao HT, Zhang SJ, et al. . Comparative effectiveness of pembrolizumab vs. Nivolumab in patients with recurrent or advanced nsclc. Sci Rep. (2020) 10:7. doi: 10.1038/s41598-020-70207-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70207-7</ArticleId><ArticleId IdType="pmc">PMC7403144</ArticleId><ArticleId IdType="pubmed">32753702</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia LL, Liu YY, Wang Y. Pd-1/pd-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. (2019) 24:S31–41. doi: 10.1634/theoncologist.2019-IO-S1-s05</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2019-IO-S1-s05</ArticleId><ArticleId IdType="pmc">PMC6394772</ArticleId><ArticleId IdType="pubmed">30819829</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu YZ, Ji Q. Tumor-associated macrophages regulate pd-1/pd-L1 immunosuppression. Front Immunol. (2022) 13:874589. doi: 10.3389/fimmu.2022.874589</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.874589</ArticleId><ArticleId IdType="pmc">PMC9110638</ArticleId><ArticleId IdType="pubmed">35592338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh C, Luong G, Sun Y. A snapshot of the pd-1/pd-L1 pathway. J Cancer. (2021) 12:2735–46. doi: 10.7150/jca.57334</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.57334</ArticleId><ArticleId IdType="pmc">PMC8040720</ArticleId><ArticleId IdType="pubmed">33854633</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang TO, Ogunniyi A, Barbee MS, Drilon A. Pembrolizumab for the treatment of pd-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther. (2016) 16:13–20. doi: 10.1586/14737140.2016.1123626</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737140.2016.1123626</ArticleId><ArticleId IdType="pmc">PMC4993158</ArticleId><ArticleId IdType="pubmed">26588948</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon EB, Rizvi NA, Hui RN, Leighl N, Balmanoukian AS, Eder JP, et al. . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. (2015) 372:2018–28. doi: 10.1056/NEJMoa1501824</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1501824</ArticleId><ArticleId IdType="pubmed">25891174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. (2016) 16:397–406. doi: 10.1517/14712598.2016.1145652</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2016.1145652</ArticleId><ArticleId IdType="pubmed">26800463</ArticleId></ArticleIdList></Reference><Reference><Citation>Sul J, Blumenthal GM, Jiang XP, He K, Keegan P, Pazdur R. Fda approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. (2016) 21:643–50. doi: 10.1634/theoncologist.2015-0498</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2015-0498</ArticleId><ArticleId IdType="pmc">PMC4861368</ArticleId><ArticleId IdType="pubmed">27026676</ArticleId></ArticleIdList></Reference><Reference><Citation>Eguren-Santamaria I, Sanmamed MF, Goldberg SB, Kluger HM, Idoate MA, Lu BY, et al. . Pd-1/pd-L1 blockers in nsclc brain metastases: challenging paradigms and clinical practice. Clin Cancer Res. (2020) 26:4186–97. doi: 10.1158/1078-0432.Ccr-20-0798</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-20-0798</ArticleId><ArticleId IdType="pubmed">32354698</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda K, Horinouchi H, Tanaka M, Higashiyama R, Shinno Y, Sato J, et al. . Efficacy of anti-pd-1 antibodies in nsclc patients with an egfr mutation and high pd-L1 expression. J Cancer Res Clin Oncol. (2021) 147:245–51. doi: 10.1007/s00432-020-03329-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00432-020-03329-0</ArticleId><ArticleId IdType="pmc">PMC7810613</ArticleId><ArticleId IdType="pubmed">32705363</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardim DL, Goodman A, Gagliato DD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. (2021) 39:154–73. doi: 10.1016/j.ccell.2020.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7878292</ArticleId><ArticleId IdType="pubmed">33125859</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zheng P. Preserving the ctla-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol Sci. (2020) 41:4–12. doi: 10.1016/j.tips.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC7210725</ArticleId><ArticleId IdType="pubmed">31836191</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of ctla-4. In: Xu J, editor. Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy. Advances in Experimental Medicine and Biology, vol. 1248 . Springer International Publishing Ag, Cham: (2020). p. 7–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32185705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Dai ZY, Wu WT, Wang ZY, Zhang N, Zhang LY, et al. . Regulatory mechanisms of immune checkpoints pd-L1 and ctla-4 in cancer. J Exp Clin Cancer Res. (2021) 40:22. doi: 10.1186/s13046-021-01987-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-021-01987-7</ArticleId><ArticleId IdType="pmc">PMC8178863</ArticleId><ArticleId IdType="pubmed">34088360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. (2019) 30:44–56. doi: 10.1093/annonc/mdy495</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdy495</ArticleId><ArticleId IdType="pmc">PMC6336005</ArticleId><ArticleId IdType="pubmed">30395155</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo HF, Li LY, Cui JW. Advances and challenges in immunotherapy of small cell lung cancer. Chin J Cancer Res. (2020) 32:115–28. doi: 10.21147/j.issn.1000-9604.2020.01.13</Citation><ArticleIdList><ArticleId IdType="doi">10.21147/j.issn.1000-9604.2020.01.13</ArticleId><ArticleId IdType="pmc">PMC7072020</ArticleId><ArticleId IdType="pubmed">32194311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. (2020) 52:17–35. doi: 10.1016/j.immuni.2019.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.12.011</ArticleId><ArticleId IdType="pubmed">31940268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterner RC, Sterner RM. Car-T cell therapy: current limitations and potential strategies. Blood Cancer J. (2021) 11:11. doi: 10.1038/s41408-021-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-021-00459-7</ArticleId><ArticleId IdType="pmc">PMC8024391</ArticleId><ArticleId IdType="pubmed">33824268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SH, Sun JW, Chen K, Ma PW, Lei Q, Xing SJ, et al. . Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. (2021) 19:7. doi: 10.1186/s12916-021-02006-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02006-4</ArticleId><ArticleId IdType="pmc">PMC8194199</ArticleId><ArticleId IdType="pubmed">34112147</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-hodgkin lymphomas. Am J Hematol. (2019) 94:S18–23. doi: 10.1002/ajh.25403</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25403</ArticleId><ArticleId IdType="pubmed">30652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. (2013) 3:388–98. doi: 10.1158/2159-8290.Cd-12-0548</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.Cd-12-0548</ArticleId><ArticleId IdType="pmc">PMC3667586</ArticleId><ArticleId IdType="pubmed">23550147</ArticleId></ArticleIdList></Reference><Reference><Citation>Song EZ, Milone MC. Pharmacology of chimeric antigen receptor-modified T cells. Annu Rev Pharmacol Toxicol. (2021) 61:805–29. doi: 10.1146/annurev-pharmtox-031720-102211</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-031720-102211</ArticleId><ArticleId IdType="pubmed">33035447</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. . Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. (2017) 377:2545–54. doi: 10.1056/NEJMoa1708566</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1708566</ArticleId><ArticleId IdType="pmc">PMC5788566</ArticleId><ArticleId IdType="pubmed">29226764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan T, Zhu LF, Chen J. Current advances and challenges in car T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. (2023) 12(1). doi: 10.1186/s40164-023-00373-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-023-00373-7</ArticleId><ArticleId IdType="pmc">PMC9883880</ArticleId><ArticleId IdType="pubmed">36707873</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S, Riddell SR. Engineering car-T cells: design concepts. Trends Immunol. (2015) 36:494–502. doi: 10.1016/j.it.2015.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.06.004</ArticleId><ArticleId IdType="pmc">PMC4746114</ArticleId><ArticleId IdType="pubmed">26169254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying ZT, Huang XF, Xiang XY, Liu YL, Kang X, Song YQ, et al. . A safe and potent anti-cd19 car T cell therapy. Nat Med. (2019) 25:947. doi: 10.1038/s41591-019-0421-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0421-7</ArticleId><ArticleId IdType="pmc">PMC7518381</ArticleId><ArticleId IdType="pubmed">31011207</ArticleId></ArticleIdList></Reference><Reference><Citation>Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen LP, et al. . Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. (2019) 25:4592–602. doi: 10.1158/1078-0432.Ccr-18-1538</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-18-1538</ArticleId><ArticleId IdType="pmc">PMC6679805</ArticleId><ArticleId IdType="pubmed">30824587</ArticleId></ArticleIdList></Reference><Reference><Citation>Firor AE, Jares A, Ma YP. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med. (2015) 240:1087–98. doi: 10.1177/1535370215584936</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370215584936</ArticleId><ArticleId IdType="pmc">PMC4935283</ArticleId><ArticleId IdType="pubmed">25956686</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu ZM, Zheng XH, Jiao DF, Zhou YG, Sun R, Wang BL, et al. . Lunx-car T cells as a targeted therapy for non-small cell lung cancer. Mol Ther-Oncolytics. (2020) 17:361–70. doi: 10.1016/j.omto.2020.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7210386</ArticleId><ArticleId IdType="pubmed">32405534</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. Car-T cells: the long and winding road to solid tumors. Cell Death Dis. (2018) 9:12. doi: 10.1038/s41419-018-0278-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0278-6</ArticleId><ArticleId IdType="pmc">PMC5833816</ArticleId><ArticleId IdType="pubmed">29449531</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Li WW, Huang KJ, Zhang Y, Kupfer G, Zhao Q. Chimeric antigen receptor T cell (Car-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. (2018) 11:18. doi: 10.1186/s13045-018-0568-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-018-0568-6</ArticleId><ArticleId IdType="pmc">PMC5809840</ArticleId><ArticleId IdType="pubmed">29433552</ArticleId></ArticleIdList></Reference><Reference><Citation>Titov A, Valiullina A, Zmievskaya E, Zaikova E, Petukhov A, Miftakhova R, et al. . Advancing car T-cell therapy for solid tumors: lessons learned from lymphoma treatment. Cancers. (2020) 12:22. doi: 10.3390/cancers12010125</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12010125</ArticleId><ArticleId IdType="pmc">PMC7016531</ArticleId><ArticleId IdType="pubmed">31947775</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. Car T-cell therapy of solid tumors. Immunol Cell Biol. (2017) 95:356–63. doi: 10.1038/icb.2016.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2016.128</ArticleId><ArticleId IdType="pubmed">28003642</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DW, Cho JY. Recent advances in allogeneic car-T cells. Biomolecules. (2020) 10:15. doi: 10.3390/biom10020263</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10020263</ArticleId><ArticleId IdType="pmc">PMC7072190</ArticleId><ArticleId IdType="pubmed">32050611</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao LJ, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. (2019) 10:2250. doi: 10.3389/fimmu.2019.02250</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02250</ArticleId><ArticleId IdType="pmc">PMC6798078</ArticleId><ArticleId IdType="pubmed">31681259</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation car T cells. Br J Cancer. (2019) 120:26–37. doi: 10.1038/s41416-018-0325-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-018-0325-1</ArticleId><ArticleId IdType="pmc">PMC6325111</ArticleId><ArticleId IdType="pubmed">30413825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS. Chimeric antigen receptor (Car) T-cell therapy for thoracic Malignancies. J Thorac Oncol. (2018) 13:16–26. doi: 10.1016/j.jtho.2017.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2017.10.001</ArticleId><ArticleId IdType="pmc">PMC5738277</ArticleId><ArticleId IdType="pubmed">29107016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke EE, Wu YL. Egfr as a pharmacological target in egfr-mutant non-small-cell lung cancer: where do we stand now? Trends Pharmacol Sci. (2016) 37:887–903. doi: 10.1016/j.tips.2016.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2016.09.003</ArticleId><ArticleId IdType="pubmed">27717507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, et al. . Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. (2014) 20:1020–8. doi: 10.1158/1078-0432.Ccr-13-1862</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-13-1862</ArticleId><ArticleId IdType="pmc">PMC3944669</ArticleId><ArticleId IdType="pubmed">24334761</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunnet M, Sorensen JB. Carcinoembryonic antigen (Cea) as tumor marker in lung cancer. Lung Cancer. (2012) 76:138–43. doi: 10.1016/j.lungcan.2011.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2011.11.012</ArticleId><ArticleId IdType="pubmed">22153832</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Wang X, Li W, Yu XF, Flores-Villanueva P, Xu-Monette ZJY, et al. . Targeting pd-L1 in non-small cell lung cancer using car T cells. Oncogenesis. (2020) 9:11. doi: 10.1038/s41389-020-00257-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-020-00257-z</ArticleId><ArticleId IdType="pmc">PMC7426958</ArticleId><ArticleId IdType="pubmed">32792499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh V. Next-generation covalent irreversible kinase inhibitors in nsclc: focus on afatinib. Biodrugs. (2015) 29:167–83. doi: 10.1007/s40259-015-0130-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-015-0130-9</ArticleId><ArticleId IdType="pmc">PMC4488453</ArticleId><ArticleId IdType="pubmed">26123538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou AJ, Chang ZNL, Lorenzini MH, Zah E, Chen YY. Tgf-B-responsive car-T cells promote anti-tumor immune function. Bioeng Transl Med. (2018) 3:75–86. doi: 10.1002/btm2.10097</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/btm2.10097</ArticleId><ArticleId IdType="pmc">PMC6063867</ArticleId><ArticleId IdType="pubmed">30065964</ArticleId></ArticleIdList></Reference><Reference><Citation>Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. (2021) 18:842–59. doi: 10.1038/s41423-020-00565-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00565-9</ArticleId><ArticleId IdType="pmc">PMC8115290</ArticleId><ArticleId IdType="pubmed">33139907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin BS, Du LK, Li HM, Zhu X, Cui L, Li XS. Tumor-infiltrating lymphocytes: warriors fight against tumors powerfully. BioMed Pharmacother. (2020) 132:9. doi: 10.1016/j.biopha.2020.110873</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110873</ArticleId><ArticleId IdType="pubmed">33068926</ArticleId></ArticleIdList></Reference><Reference><Citation>Veatch JR, Simon S, Riddell SR. Tumor-infiltrating lymphocytes make inroads in non-small-cell lung cancer. Nat Med. (2021) 27:1339–41. doi: 10.1038/s41591-021-01445-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01445-z</ArticleId><ArticleId IdType="pubmed">34385706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G, et al. . A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer. (1996) 78:244–51. doi: 10.1002/(sici)1097-0142(19960715)78:2&lt;244::Aid-cncr9&gt;3.0.Co;2-l</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1097-0142(19960715)78:2&lt;244::Aid-cncr9&gt;3.0.Co;2-l</ArticleId><ArticleId IdType="pubmed">8673999</ArticleId></ArticleIdList></Reference><Reference><Citation>Creelan B, Wang C, Teer J, Toloza E, Mullinax J, Yao JQ, et al. . Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (Til) in non-small cell lung cancer (Nsclc): A phase I trial. Cancer Res. (2020) 80:2. doi: 10.1158/1538-7445.Am2020-ct056</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.Am2020-ct056</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clinics North America. (2016) 25:601. doi: 10.1016/j.soc.2016.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soc.2016.02.011</ArticleId><ArticleId IdType="pubmed">27261918</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez P, Peters S, Stammers T, Soria JC. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer. Clin Cancer Res. (2019) 25:2691–8. doi: 10.1158/1078-0432.Ccr-18-3904</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-18-3904</ArticleId><ArticleId IdType="pubmed">30642913</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy. Clinics Chest Med. (2020) 41:237. doi: 10.1016/j.ccm.2020.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2020.02.010</ArticleId><ArticleId IdType="pubmed">32402359</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Molina J, Moyano-Galceran L, Single A, Gultekin O, Alsalhi S, Lehti K. Chemotherapy as a regulator of extracellular matrix-cell communication: implications in therapy resistance. Semin Cancer Biol. (2022) 86:224–36. doi: 10.1016/j.semcancer.2022.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2022.03.012</ArticleId><ArticleId IdType="pubmed">35331851</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Hussein A, Manoto SL, Ombinda-Lemboumba S, Alrowaili ZA, Mthunzi-Kufa P. A review of chemotherapy and photodynamic therapy for lung cancer treatment. Anti-Cancer Agents Med Chem. (2020) 21:149–61. doi: 10.2174/1871520620666200403144945</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871520620666200403144945</ArticleId><ArticleId IdType="pubmed">32242788</ArticleId></ArticleIdList></Reference><Reference><Citation>Estanqueiro M, Amaral MH, Conceição J, Sousa Lobo JM. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloids Surfaces B: Biointerfaces. (2015) 126:631–48. doi: 10.1016/j.colsurfb.2014.12.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2014.12.041</ArticleId><ArticleId IdType="pubmed">25591851</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Mai B, Nie Y, Yuan C, Xiang M, Shi Z, et al. . In vitro and in vivo demonstration of ultraefficient and broad-spectrum antibacterial agents for photodynamic antibacterial chemotherapy. ACS Appl Mater Interfaces. (2021) 13:11588–96. doi: 10.1021/acsami.0c20837</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.0c20837</ArticleId><ArticleId IdType="pubmed">33656316</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie ZJ, Fan TJ, An J, Choi W, Duo YH, Ge YQ, et al. . Emerging combination strategies with phototherapy in cancer nanomedicine. Chem Soc Rev. (2020) 49:8065–87. doi: 10.1039/d0cs00215a</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0cs00215a</ArticleId><ArticleId IdType="pubmed">32567633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K, Ma Z, Li J, Tang M, Lindstrom A, Ramachandran M, et al. . Single small molecule-assembled mitochondria targeting nanofibers for enhanced photodynamic cancer therapy in vivo . Adv Funct Mater. (2020) 31(10). doi: 10.1002/adfm.202008460</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.202008460</ArticleId><ArticleId IdType="pmc">PMC10338027</ArticleId><ArticleId IdType="pubmed">37441230</ArticleId></ArticleIdList></Reference><Reference><Citation>Janas K, Boniewska-Bernacka E, Dyrda G, Słota R. Porphyrin and phthalocyanine photosensitizers designed for targeted photodynamic therapy of colorectal cancer. Bioorganic Med Chem. (2021) 30. doi: 10.1016/j.bmc.2020.115926</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2020.115926</ArticleId><ArticleId IdType="pubmed">33341498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Liang X, Gao C, Zhao R, Zhang N, Wang S, et al. . Ultrasound triggered conversion of porphyrin/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal cancer. ACS Nano. (2018) 12:7312–26. doi: 10.1021/acsnano.8b03674</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b03674</ArticleId><ArticleId IdType="pubmed">29901986</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH. Photosensitizers in clinical pdt. Photodiagnosis Photodyn Ther. (2004) 1:27–42. doi: 10.1016/s1572-1000(04)00007-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1572-1000(04)00007-9</ArticleId><ArticleId IdType="pubmed">25048062</ArticleId></ArticleIdList></Reference><Reference><Citation>Triesscheijn M, Baas P, Schellens JHM, Stewart FA. Photodynamic therapy in oncology. Oncologist. (2006) 11:1034–44. doi: 10.1634/theoncologist.11-9-1034</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.11-9-1034</ArticleId><ArticleId IdType="pubmed">17030646</ArticleId></ArticleIdList></Reference><Reference><Citation>Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. (2002) 2:277–88. doi: 10.1038/nrc776</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc776</ArticleId><ArticleId IdType="pubmed">12001989</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleinick NL, Morris RL, Belichenko T. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. (2002) 1:1–21. doi: 10.1039/b108586g</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b108586g</ArticleId><ArticleId IdType="pubmed">12659143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji B, Wei MJ, Yang B. Recent advances in nanomedicines for photodynamic therapy (Pdt)-driven cancer immunotherapy. Theranostics. (2022) 12:434–58. doi: 10.7150/thno.67300</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.67300</ArticleId><ArticleId IdType="pmc">PMC8690913</ArticleId><ArticleId IdType="pubmed">34987658</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun XK, Sun J, Lv JK, Dong B, Liu M, Liu JS, et al. . Ce6-C6-tpz co-loaded albumin nanoparticles for synergistic combined pdt-chemotherapy of cancer. J Mat Chem B. (2019) 7:5797–807. doi: 10.1039/c9tb01346f</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c9tb01346f</ArticleId><ArticleId IdType="pubmed">31483422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupu M, Maillard P, Mispelter J, Poyer F, Thomas CD. A glycoporphyrin story: from chemistry to pdt treatment of cancer mouse models. Photochem Photobiol Sci. (2018) 17:1599–611. doi: 10.1039/c8pp00123e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c8pp00123e</ArticleId><ArticleId IdType="pubmed">29855017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Yang B, Lv C, Chen T, Sun L, Sun L, et al. . Amino porphyrin-peptide assemblies induce ribosome damage and cancer stem cell inhibition for an enhanced photodynamic therapy. Biomaterials. (2022) 289. doi: 10.1016/j.biomaterials.2022.121812</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2022.121812</ArticleId><ArticleId IdType="pubmed">36152516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou L, Zhou S, Tan S, Xiang M, Wang W, Yuan C, et al. . Amplifying the efficacy of ala-based prodrugs for photodynamic therapy using nanotechnology. Front Pharmacol. (2023) 14:1137707. doi: 10.3389/fphar.2023.1137707</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1137707</ArticleId><ArticleId IdType="pmc">PMC10008889</ArticleId><ArticleId IdType="pubmed">36923350</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M, Zhou Q, Shi Z, Wang X, Li M, Jia Y, et al. . A review of light sources and enhanced targeting for photodynamic therapy. Curr Med Chem. (2021) 28:6437–57. doi: 10.2174/0929867328666210121122106</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867328666210121122106</ArticleId><ArticleId IdType="pubmed">33475053</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Wu J, Pang X, Jiang Y, Wang P, Leung AW, et al. . Discovery and development of natural products and their derivatives as photosensitizers for photodynamic therapy. Curr Med Chem. (2018) 25:839–60. doi: 10.2174/0929867324666170823143137</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170823143137</ArticleId><ArticleId IdType="pubmed">28831916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao W, Yang C, Li FY, Wu JH, Wang N, Ding Q, et al. . Molecular design of conjugated small molecule nanoparticles for synergistically enhanced ptt/pdt. Nano-Micro Lett. (2020) 12:14. doi: 10.1007/s40820-020-00474-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40820-020-00474-6</ArticleId><ArticleId IdType="pmc">PMC7770699</ArticleId><ArticleId IdType="pubmed">34138129</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Qiao G, Han Y, Shen E, Alfranca G, Tan H, et al. . Targeted theranostics of lung cancer: pd-L1-guided delivery of gold nanoprisms with chlorin E6 for enhanced imaging and photothermal/photodynamic therapy. Acta Biomaterialia. (2020) 117:361–73. doi: 10.1016/j.actbio.2020.09.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2020.09.040</ArticleId><ArticleId IdType="pubmed">33007481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Zhou YX, He WD, Ren XM, Zhang MZ, Jiang Y, et al. . Platelet-armored nanoplatform to harmonize janus-faced ifn-Γ against tumor recurrence and metastasis. J Control Release. (2021) 338:33–45. doi: 10.1016/j.jconrel.2021.08.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.08.020</ArticleId><ArticleId IdType="pubmed">34391837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Zhong Y, Wu S, Yan M, Cao Y, Mou NL, et al. . Cell membrane camouflaged biomimetic nanoparticles: focusing on tumor theranostics. Mater Today Bio. (2022) 14:16. doi: 10.1016/j.mtbio.2022.100228</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2022.100228</ArticleId><ArticleId IdType="pmc">PMC8898969</ArticleId><ArticleId IdType="pubmed">35265826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Hao D, Wu Q, Li Y, Pei Q, Sun T, et al. . Porphyrin cholesterol conjugates for enhanced photodynamic immunotherapy toward lung cancer. ACS Appl Mater Interfaces. (2023) 15:35927–38. doi: 10.1021/acsami.3c05825</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.3c05825</ArticleId><ArticleId IdType="pubmed">37471051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang HL, Xue YA, Li BW, Xu XJ, Zhang F, Guo JJ, et al. . Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with sirna against patient-derived pancreatic carcinoma. Acta Pharm Sin B. (2022) 12:3410–26. doi: 10.1016/j.apsb.2022.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2022.02.007</ArticleId><ArticleId IdType="pmc">PMC9366227</ArticleId><ArticleId IdType="pubmed">35967289</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone CB, Friedberg JS, Glatstein E, Stevenson JP, Sterman DH, Hahn SM, et al. . Photodynamic therapy for the treatment of non-small cell lung cancer. J Thorac Dis. (2012) 4:63–75. doi: 10.3978/j.issn.2072-1439.2011.11.05</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2072-1439.2011.11.05</ArticleId><ArticleId IdType="pmc">PMC3256541</ArticleId><ArticleId IdType="pubmed">22295169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad R, Fu J, He NY, Li S. Advanced gold nanomaterials for photothermal therapy of cancer. J Nanosci Nanotechnol. (2016) 16:67–80. doi: 10.1166/jnn.2016.10770</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jnn.2016.10770</ArticleId><ArticleId IdType="pubmed">27398434</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam J, Son S, Ochyl LJ, Kuai R, Schwendeman A, Moon JJ. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. (2018) 9:13. doi: 10.1038/s41467-018-03473-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03473-9</ArticleId><ArticleId IdType="pmc">PMC5852008</ArticleId><ArticleId IdType="pubmed">29540781</ArticleId></ArticleIdList></Reference><Reference><Citation>Oei AL, Vriend LEM, Crezee J, Franken NAP, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol. (2015) 10:13. doi: 10.1186/s13014-015-0462-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13014-015-0462-0</ArticleId><ArticleId IdType="pmc">PMC4554295</ArticleId><ArticleId IdType="pubmed">26245485</ArticleId></ArticleIdList></Reference><Reference><Citation>Yata T, Takahashi Y, Tan MM, Nakatsuji H, Ohtsuki S, Murakami T, et al. . DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy. Biomaterials. (2017) 146:136–45. doi: 10.1016/j.biomaterials.2017.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2017.09.014</ArticleId><ArticleId IdType="pubmed">28918263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Lu GH, Wen XL, Li F, Ji XY, Li QQ, et al. . Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy. J Control Release. (2020) 326:131–9. doi: 10.1016/j.jconrel.2020.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.06.015</ArticleId><ArticleId IdType="pubmed">32580043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XG, Tang JJ, Li C, Lu Y, Cheng LL, Liu J. A targeting black phosphorus nanoparticle based immune cells nano-regulator for photodynamic/photothermal and photo-immunotherapy. Bioact Mater. (2021) 6:472–89. doi: 10.1016/j.bioactmat.2020.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2020.08.024</ArticleId><ArticleId IdType="pmc">PMC7493086</ArticleId><ArticleId IdType="pubmed">32995674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Zhang Q, Luo XF, Li J, He H, Yang F, et al. . Magnetic graphene-based nanotheranostic agent for dual-modality mapping guided photothermal therapy in regional lymph nodal metastasis of pancreatic cancer. Biomaterials. (2014) 35:9473–83. doi: 10.1016/j.biomaterials.2014.07.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2014.07.064</ArticleId><ArticleId IdType="pubmed">25175596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Zhang Y, Sun L, Wang J, Zhao Z, Huang Z, et al. . Modulated ultrasmall Γ-fe2o3 nanocrystal assemblies for switchable magnetic resonance imaging and photothermal-ferroptotic-chemical synergistic cancer therapy. Adv Funct Mater. (2022) 33(5). doi: 10.1002/adfm.202211251</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.202211251</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang CT, Gong SM, Li XC, Yu MY, Qian CG, et al. . A nanoscale photothermal agent based on a metal-organic coordination polymer as a drug-loading framework for effective combination therapy. Acta Biomaterialia. (2019) 94:435–46. doi: 10.1016/j.actbio.2019.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2019.06.014</ArticleId><ArticleId IdType="pubmed">31216493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Barhoumi A, Tong R, Wang WP, Ji TJ, Deng XR, et al. . Batio3-core au-shell nanoparticles for photothermal therapy and bimodal imaging. Acta Biomaterialia. (2018) 72:287–94. doi: 10.1016/j.actbio.2018.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2018.03.029</ArticleId><ArticleId IdType="pmc">PMC5938150</ArticleId><ArticleId IdType="pubmed">29578086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye XY, Liang X, Chen Q, Miao QW, Chen XL, Zhang XD, et al. . Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS Nano. (2019) 13:2956–68. doi: 10.1021/acsnano.8b07371</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b07371</ArticleId><ArticleId IdType="pubmed">30789699</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N, Rodrigues CF, Moreira AF, Correia IJ. Overview of the application of inorganic nanomaterials in cancer photothermal therapy. Biomater Sci. (2020) 8:2990–3020. doi: 10.1039/d0bm00222d</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0bm00222d</ArticleId><ArticleId IdType="pubmed">32355937</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Dwivedi M, Ahmad H, Chadchan SB, Arya A, Sikandar R, et al. . Cd44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. Nanomed-Nanotechnol Biol Med. (2018) 14:327–37. doi: 10.1016/j.nano.2017.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2017.10.010</ArticleId><ArticleId IdType="pubmed">29129754</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang ZG, Lv FM, Wang J, Ca SJ, Liu ZP, Liu Y, et al. . Rgd-modified pegylated paclitaxel nanocrystals with enhanced stability and tumor-targeting capability. Int J Pharm. (2019) 556:217–25. doi: 10.1016/j.ijpharm.2018.12.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.12.023</ArticleId><ArticleId IdType="pubmed">30557679</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng FF, Wang JP, Ping QN, Yeo Y. Camouflaging nanoparticles for ratiometric delivery of therapeutic combinations. Nano Lett. (2019) 19:1479–87. doi: 10.1021/acs.nanolett.8b04017</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.8b04017</ArticleId><ArticleId IdType="pmc">PMC6417971</ArticleId><ArticleId IdType="pubmed">30707035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Mongia A, Gulati S, Singh P, Diwan A, Shukla S. Emerging theranostic gold nanostructures to combat cancer: novel probes for combinatorial immunotherapy and photothermal therapy. Cancer Treat Res Commun. (2020) 25:100258. doi: 10.1016/j.ctarc.2020.100258</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctarc.2020.100258</ArticleId><ArticleId IdType="pubmed">33307507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HS, Gu DH, Xia SJ, Chen FH, You CQ, Sun BW. One-for-all intelligent core-shell nanoparticles for tumor-specific photothermal-chemodynamic synergistic therapy. Biomater Sci. (2021) 9:1020–33. doi: 10.1039/d0bm01734e</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0bm01734e</ArticleId><ArticleId IdType="pubmed">33325928</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z, Niu T, Shao Q, Yue J, Zhang H, Tong L, et al. . Pt–se-bonded nanoprobe for high-fidelity detection of non-small cell lung cancer and enhancement of nir ii photothermal therapy. Anal Chem. (2023) 95:18426–35. doi: 10.1021/acs.analchem.3c03511</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.3c03511</ArticleId><ArticleId IdType="pubmed">38051938</ArticleId></ArticleIdList></Reference><Reference><Citation>Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. (2001) 28:36–41. doi: 10.1016/s0093-7754(01)90211-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0093-7754(01)90211-8</ArticleId><ArticleId IdType="pubmed">11395851</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, et al. . Melatonin suppresses tumor angiogenesis by inhibiting hif-1α Stabilization under hypoxia. J Pineal Res. (2010) 48:178–84. doi: 10.1111/j.1600-079X.2009.00742.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2009.00742.x</ArticleId><ArticleId IdType="pubmed">20449875</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza GL. Hif-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. (2000) 88:1474–80. doi: 10.1152/jappl.2000.88.4.1474</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.2000.88.4.1474</ArticleId><ArticleId IdType="pubmed">10749844</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N, Wang LC, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. . Loss of hif-1α in endothelial cells disrupts a hypoxia-driven vegf autocrine loop necessary for tumorigenesis. Cancer Cell. (2004) 6:485–95. doi: 10.1016/j.ccr.2004.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2004.09.026</ArticleId><ArticleId IdType="pubmed">15542432</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordgren IK, Tavassoli A. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem Soc Rev. (2011) 40:4307–17. doi: 10.1039/c1cs15032d</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c1cs15032d</ArticleId><ArticleId IdType="pubmed">21483947</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, et al. . Inhibition of hypoxia-induced angiogenesis by trichostatin a via suppression of hif-1a activity in human osteosarcoma. J Exp Clin Cancer Res. (2006) 25(4):593–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17310851</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y-Z, Wang ZU, Wang H, Lu J, Yu S-H, Jiang H-L. Singlet oxygen-engaged selective photo-oxidation over pt nanocrystals/porphyrinic mof: the roles of photothermal effect and pt electronic state. J Am Chem Soc. (2017) 139:2035–44. doi: 10.1021/jacs.6b12074</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.6b12074</ArticleId><ArticleId IdType="pubmed">28103670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung N, Sohn Y, Park JH, Nahm KS, Kim P, Yoo SJ. High-performance ptcux@Pt core-shell nanoparticles decorated with nanoporous pt surfaces for oxygen reduction reaction. Appl Catalysis B: Environ. (2016) 196:199–206. doi: 10.1016/j.apcatb.2016.05.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apcatb.2016.05.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z-P, Tan A-D, Fu Z-Y, Piao J-H, Liang Z-X. Oxygen reduction reaction on single pt nanoparticle. J Energy Chem. (2020) 49:323–6. doi: 10.1016/j.jechem.2020.02.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jechem.2020.02.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Liu S, Wang Y, He X, Zhang Q, Qi Y, et al. . Synergistic enhancement of immunological responses triggered by hyperthermia sensitive pt nps via nir laser to inhibit cancer relapse and metastasis. Bioact Mater. (2022) 7:389–400. doi: 10.1016/j.bioactmat.2021.05.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2021.05.030</ArticleId><ArticleId IdType="pmc">PMC8379359</ArticleId><ArticleId IdType="pubmed">34466740</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MY, Hou ZY, Wang M, Li CX, Lin J. Recent advances in hyperthermia therapy-based synergistic immunotherapy. Adv Mater. (2021) 33:29. doi: 10.1002/adma.202004788</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202004788</ArticleId><ArticleId IdType="pubmed">33289219</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MY, Hou ZY, Wang M, Wang MF, Dang PP, Liu JH, et al. . Cu2Mos4/au heterostructures with enhanced catalase-like activity and photoconversion efficiency for primary/metastatic tumors eradication by phototherapy-induced immunotherapy. Small. (2020) 16:14. doi: 10.1002/smll.201907146</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201907146</ArticleId><ArticleId IdType="pubmed">32162784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kepp O, Marabelle A, Zitvogel L, Kroemer G. Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol. (2020) 17:49–64. doi: 10.1038/s41571-019-0272-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-019-0272-7</ArticleId><ArticleId IdType="pubmed">31595049</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong L, Zhang Y, Li WS, Su ZG, Fadhil JI, Zhang C. Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy. Biomaterials. (2019) 225:9. doi: 10.1016/j.biomaterials.2019.119515</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2019.119515</ArticleId><ArticleId IdType="pubmed">31590119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao WD, Guo ZY, Dai YC, Nie J, Li BY, Pei HL, et al. . Lnc crybg3 inhibits tumor growth by inducing M phase arrest. J Cancer. (2019) 10:2764–70. doi: 10.7150/jca.31703</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.31703</ArticleId><ArticleId IdType="pmc">PMC6584918</ArticleId><ArticleId IdType="pubmed">31258784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei HL, Hu WT, Guo ZY, Chen HY, Ma J, Mao WD, et al. . Long noncoding rna crybg3 blocks cytokinesis by directly binding G-actin. Cancer Res. (2018) 78:4563–72. doi: 10.1158/0008-5472.Can-18-0988</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-18-0988</ArticleId><ArticleId IdType="pmc">PMC6095725</ArticleId><ArticleId IdType="pubmed">29934435</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Yuan G, Xu Y, Gao Y, Mao Q, Zhang Y, et al. . Photoacoustic and magnetic resonance imaging-based gene and photothermal therapy using mesoporous nanoagents. Bioact Mater. (2022) 9:157–67. doi: 10.1016/j.bioactmat.2021.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2021.07.025</ArticleId><ArticleId IdType="pmc">PMC8586268</ArticleId><ArticleId IdType="pubmed">34820563</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Zhou Z, Yang W, L-s L, Wang S, Niu G, et al. . Endoplasmic reticulum targeting to amplify immunogenic cell death for cancer immunotherapy. Nano Lett. (2020) 20:1928–33. doi: 10.1021/acs.nanolett.9b05210</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.9b05210</ArticleId><ArticleId IdType="pubmed">32073871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Zhang F, Deng H, Lin L, Wang S, Kang F, et al. . Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. ACS Nano. (2019) 14:620–31. doi: 10.1021/acsnano.9b07212</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.9b07212</ArticleId><ArticleId IdType="pubmed">31877023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Zhu G, Wang S, Yu G, Yang Z, Lin L, et al. . In situ dendritic cell vaccine for effective cancer immunotherapy. ACS Nano. (2019) 13:3083–94. doi: 10.1021/acsnano.8b08346</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b08346</ArticleId><ArticleId IdType="pubmed">30835435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J, Li L, Yang Z, Chen X. Phototherapy meets immunotherapy: A win–win strategy to fight against cancer. Nanophotonics. (2021) 10:3229–45. doi: 10.1515/nanoph-2021-0209</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/nanoph-2021-0209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MM, Darafsheh A. Light sources and dosimetry techniques for photodynamic therapy. Photochem Photobiol. (2020) 96:280–94. doi: 10.1111/php.13219</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/php.13219</ArticleId><ArticleId IdType="pubmed">32003006</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasco JA, Ravi S, Perez JD, Hagaman DE, Melancon MP. Understanding nanoparticle toxicity to direct a safe-by-design approach in cancer nanomedicine. Nanomaterials. (2020) 10(11). doi: 10.3390/nano10112186</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nano10112186</ArticleId><ArticleId IdType="pmc">PMC7692849</ArticleId><ArticleId IdType="pubmed">33147800</ArticleId></ArticleIdList></Reference><Reference><Citation>Overchuk M, Weersink RA, Wilson BC, Zheng G. Photodynamic and photothermal therapies: synergy opportunities for nanomedicine. ACS Nano. (2023) 17:7979–8003. doi: 10.1021/acsnano.3c00891</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c00891</ArticleId><ArticleId IdType="pmc">PMC10173698</ArticleId><ArticleId IdType="pubmed">37129253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang YF, Liu Y, Fang SY, Ji M. Gold nanoshells coated 5-aminolevulinic liposomes for photothermal-photodynamic antitumor therapy. J Nanosci Nanotechnol. (2020) 20:1–14. doi: 10.1166/jnn.2020.168860</Citation><ArticleIdList><ArticleId IdType="doi">10.1166/jnn.2020.168860</ArticleId><ArticleId IdType="pubmed">31383134</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G, Jiang YW, Guo Y, Jia HR, Cheng X, Deng Y, et al. . Enzyme-mediated tumor starvation and phototherapy enhance mild-temperature photothermal therapy. Adv Funct Mater. (2020) 30(16). doi: 10.1002/adfm.201909391</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201909391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu IL, Liu T-I, Lin H-C, Chang S-H, Lo C-L, Chiang W-H, et al. . Ir780-loaded zwitterionic polymeric nanoparticles with acidity-induced agglomeration for enhanced tumor retention. Eur Polymer J. (2020) 122. doi: 10.1016/j.eurpolymj.2019.109400</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eurpolymj.2019.109400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha J-H, Kim Y-J. Photodynamic and cold atmospheric plasma combination therapy using polymeric nanoparticles for the synergistic treatment of cervical cancer. Int J Mol Sci. (2021) 22(3). doi: 10.3390/ijms22031172</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031172</ArticleId><ArticleId IdType="pmc">PMC7865232</ArticleId><ArticleId IdType="pubmed">33504007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong H, Wang Y, Li H, Jin Q, Ji J. Dual ph-responsive 5-aminolevulinic acid pseudopolyrotaxane prodrug micelles for enhanced photodynamic therapy. Chem Commun. (2016) 52:3966–9. doi: 10.1039/c6cc00450d</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c6cc00450d</ArticleId><ArticleId IdType="pubmed">26882232</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Xiao Y, Li W, Yang Q, Tan L, Jia Y, et al. . Photosensitizer micelles together with ido inhibitor enhance cancer photothermal therapy and immunotherapy. Adv Sci. (2018) 5(5). doi: 10.1002/advs.201700891</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.201700891</ArticleId><ArticleId IdType="pmc">PMC5979747</ArticleId><ArticleId IdType="pubmed">29876215</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Q, Lin H, Wu J, Pang X, Zhou Q, Jiang Y, et al. . Pyridine-embedded phenothiazinium dyes as lysosome-targeted photosensitizers for highly efficient photodynamic antitumor therapy. J Med Chem. (2020) 63:4896–907. doi: 10.1021/acs.jmedchem.0c00280</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c00280</ArticleId><ArticleId IdType="pubmed">32267685</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Zhang W, Ouyang Y, Tan Y, Zhao S, Chen Y, et al. . Hemoglobin-decorated boron-carbon nanosheets with catalytic ability and near-infrared ii light response for tumor photothermal-chemodynamic therapy. ACS Appl Nano Mater. (2023) 6:7572–81. doi: 10.1021/acsanm.3c00726</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsanm.3c00726</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasulu YG, Mozhi A, Goswami N, Yao Q, Xie J. Traceable nanocluster–prodrug conjugate for chemo-photodynamic combinatorial therapy of non-small cell lung cancer. ACS Appl Bio Mater. (2021) 4:3232–45. doi: 10.1021/acsabm.0c01611</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.0c01611</ArticleId><ArticleId IdType="pubmed">35014410</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Kim H, Lim SC, Lim K, Lee ES, Oh KT, et al. . Gold nanocluster-loaded hybrid albumin nanoparticles with fluorescence-based optical visualization and photothermal conversion for tumor detection/ablation. J Control Release. (2019) 304:7–18. doi: 10.1016/j.jconrel.2019.04.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.04.036</ArticleId><ArticleId IdType="pubmed">31028785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharathiraja S, Moorthy MS, Manivasagan P, Seo H, Lee KD, Oh J. Chlorin E6 conjugated silica nanoparticles for targeted and effective photodynamic therapy. Photodiagnosis Photodyn Ther. (2017) 19:212–20. doi: 10.1016/j.pdpdt.2017.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pdpdt.2017.06.001</ArticleId><ArticleId IdType="pubmed">28583295</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J, Zhao L, Zhu X, Sun Y, Feng W, Gao Y, et al. . Hollow silica nanoparticles loaded with hydrophobic phthalocyanine for near-infrared photodynamic and photothermal combination therapy. Biomaterials. (2013) 34:7905–12. doi: 10.1016/j.biomaterials.2013.07.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2013.07.027</ArticleId><ArticleId IdType="pubmed">23891514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Zhong H, Pan W, Li Y, Chen Y, Li N, et al. . Programmed release of dihydroartemisinin for synergistic cancer therapy using a caco3 mineralized metal–organic framework. Angewandte Chemie Int Edition. (2019) 58:14134–9. doi: 10.1002/anie.201907388</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201907388</ArticleId><ArticleId IdType="pubmed">31389105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Sun Y, Wang J, Zhou X, Kong X, Meng J, et al. . Dual-responsive triple-synergistic fe-mof for tumor theranostics. ACS Nano. (2023) 17:9003–13. doi: 10.1021/acsnano.2c10310</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c10310</ArticleId><ArticleId IdType="pubmed">37116070</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin D, Zhu Y, Liu M, Yu W, Yu J, Zheng X, et al. . A leaking-proof theranostic nanoplatform for tumor-targeted and dual-modality imaging-guided photodynamic therapy. BME Front. (2023) 4. doi: 10.34133/bmef.0015</Citation><ArticleIdList><ArticleId IdType="doi">10.34133/bmef.0015</ArticleId><ArticleId IdType="pmc">PMC10085250</ArticleId><ArticleId IdType="pubmed">37849678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>